Table 3.

Data for the adult Personalized OncoGenomics (POG) population describing how often the data was felt to be informative or actionable by the treating medical oncologist and the clinician-assessed response to any POG-informed treatment that was delivered

	N = 100 adults	Percentage
Sufficient tissue for POG analysis	78	78%
Insufficient tissue for POG analysis
Biopsy content too low for sequencing	16	16%
Unable to biopsy due to specific patient factors	6	6%
Informative	65	65% total; 83% when sequencing was possible
Actionable	55	55% total; 71% when sequencing was possible
Patients received POG-informed treatment	34	34% total; 44% when sequencing was possible; 62% when there was something actionable identified
Well patients eligible for POG-informed treatment who did not receive therapy	8	8%
No treatment available	2	2%
Not eligible for identified clinical trial	2	2%
Already on an alternative clinical trial	1	1%
Unknown	3	3%
Clinician-assessed clinical or radiographic improvement in cancer (including stable disease)	14	41% (14 of 34)
Actionable target identified but the patient was too unwell or death before POG-informed therapy could be offered	13	24% (13 of 55)
Amended or clarified the diagnosis or primary site	5	5% total; 6% when sequencing possible